Viral Vector Development Service Market Analysis & Forecast 2024-2030

Viral Vector Development Service Market by Product Type ( Retroviral Vectors, Lentiviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, vaccinia vector, herpes simplex victor, baculovirus vector) by Application / End User (Pharmaceutical Manufacturers, Biotechnology Companies, Research Institutes) by Industry Analysis, Volume, Share, Growth, Challenges, Trends, and Forecast 2024-2030, Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, Africa)

Report Code: PSMR- 75          Category: Biotechnology           Region :  Global         Report Format :                  

 Download Free Sample

 Table of Contents

Global Viral Vector Development Service Market is expected to reach USD 4483.35 million by 2031 with CAGR of 19.2 % between 2025 and 2031

Viral vector is gene transfer therapy use to manipulate and modify specific cell type or tissue. It is most effective gene manipulation technique used globally. Various virus types are use in Viral vector process to provide either transient or permanent gene delivery to cells. Viral vector process based on virus included are:

  • Retroviral Vectors - Retroviruses are stably integrate their genomes into host cell chromosomes. These viruses are positive strand RNA viruses and can enter virtually any mammalian cell type. Retroviruses can carry foreign genes of around 8 kb.
  • Lentiviral Vectors - Lentiviruses are a subgroup of the retrovirus family and allow stable, long-term expression into the host cell genome.
  • Adenoviral Vectors - Adenoviruses are DNA viruses can transiently transduce nearly any mammalian cell type. The adenovirus enters target cells by binding to the Coxsackie/Adenovirus receptor (CAR) . The packaging capacity of adenoviruses is 7–8 kb.
  • Adeno-associated Viral Vectors - Adeno-associated viruses are capable of transducing a broad range of dividing and non-dividing cells types, with a helper virus like adenovirus or herpes virus to produce recombinant virions in packaging cells. Adeno-associated viruses have packaging capacity of up to 4.9 kb.
  • Other Viral Vectors - Other viral vector systems based on vaccinia virus, herpes simplex virus, baculovirus.

Viral Vector Development Service Market

Viral Vectors technique relies completely on viruses . The choice of virus for Viral Vectors process depend on :

  • Safety: Pathogenic viruses are used occasionally to create viral vectors, they are modified in specific way to minimize handling risk.
  • Low toxicity: The viral vector should have as minimal as possible effect on tissue or cell it infects. It has vital importance in studies requiring gene delivery in vivo as immune response will get developed in organism against foreign cell body.
  • Stability: Some viruses are genetically unstable and can rapidly rearrange their genomes. Hence unstable vectors are usually avoided in Viral Vectors process.
  • Cell type specificity: Most viral vectors are constructed to infect as wide a range of cell types as possible and sometimes the opposite is preferred.
  • Selection: Viral vectors should contain selectable properties like resistance to a certain antibiotic, so that the cells that have taken up the viral vector can be isolated.

Viral Vector Development Service Market : End User/Application

  • Pharmaceutical Manufacturers
  • Biotechnology Companies
  • Research Institutes

Viral Vector Development Service Market : Product Type

  • Retroviral Vectors
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Adeno-associated Viral Vectors
  • Other Viral Vectors

Viral Vector Development Service Market : Competition Analysis

This reports covers in-depth analysis of major players of Viral Vector Development Service Market. Competition Analysis included in study covers Company Profile, Products, Services and Solutions, Viral Vector Development Service Revenue (Value), Recent Developments . Some of key players in market are:
  • Kaneka Eurogentec
  • FinVector
  • Brammer Bio
  • Cell and Gene Therapy Catapult
  • FUJIFILM Diosynth Biotechnologies
  • Sanofi
  • Spark Therapeutics
  • Cobra Biologics
  • UniQure and MassBiologics
  • Renova Therapeutics
  • Shenzhen SiBiono GeneTech
  • Thermo Fisher Scientific

Global Viral Vector Development Service Market: Regional Analysis

  • North America
    • U.S.A
    • Canada
  • Europe
    • France
    • Germany
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South East Asia
  • Latin America
    • Brazil
  • Middle East and Africa

Global Viral Vector Development Service Market Report delivers a comprehensive analysis of the following parameters:

  • Market Forecast for 2024-2030
  • Market growth drivers
  • Challenges and Opportunities
  • Emerging and Current market trends
  • Market player Capacity, Production, Revenue (Value)
  • Supply (Production), Consumption, Export, Import analysis
  • End user/application Analysis

Report Coverage

Parameters Details

Base Year

2024

Historical Data

2018-2023

Forecast Data

2024-2030

Base Year Value (2024)

USD 1311.2 million

Forecast Value (2031)

USD 4483.35 million

CAGR (2025-2030)

19.2 %

Regional Scope

North America, Europe, Asian Pacific, Latin America, Middle East and Africa, and ROW


Frequently Asked Questions (FAQ)


Viral Vector Development Service Market was valued at around USD 1311.2 million in 2023 & estimated to reach USD 4483.35 million by 2030.




Viral Vector Development Service Market is likely to grow at Compound Annual Growth Rate (CAGR) of 19.2% between 2024 to 2030.




Viral Vector Development Service Market is dominated by the Retroviral Vectors segment and the North America region holds the highest market share in 2023



Some of the top key players of the Viral Vector Development Service Market are Kaneka Eurogentec,FinVector,Brammer Bio,Cell and Gene Therapy Catapult,FUJIFILM Diosynth Biotechnologies,Sanofi,Spark Therapeutics,Cobra Biologics,UniQure and MassBiologics,Renova Therapeutics,Shenzhen SiBiono GeneTech,Thermo Fisher Scientific




Primary driving factors for the growth of the Viral Vector Development Service Market include Rising cases of the cancer patients along with technological development in the healthcare industry




Yes, the report includes COVID 19 impact on the market.



Purchase Options

    Cloud Access $2450

    Corporate User $3550

        Licence

    Enterprise Licence $4050

Inquire Before Buying

Please fill below details:






    ×
    Free Customization

    We are committed to offering 100 % free customization while purchasing.



      Access FREE Sample

      Receive a detailed insight into the Viral Vector Development Service Market research study with our FREE sample report delivered straight to your email. The report covers major market factors such as Revenue, Forecast, Top companies insight, Regional analysis, Market trends & more.

       Download Free Sample




        ×